Hugo Jourdain

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Electronic Health Record

Machine Learning

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD open 10 (1) (2024)
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD open 10 (1) (2024)
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD open 10 (1) (2024)
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD open 10 (1) (2024)
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD open 10 (1) (2024)
Hugo Jourdain, Lea Hoisnard, Emilie Sbidian, Mahmoud Zureik
Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)